Global neuroendocrine carcinoma market to reach $475 million by 2019; report

4 July 2012

The global Neuroendocrine carcinoma therapeutics market was worth $127 million in 2011 and now the market is forecast to increase at compound annual growth rate (CAGR) of 17.9% to reach $475 million by 2019, according to a new report from GlobalData, titled Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market.

The high growth is primarily attributed to the advent of approved drugs, Pfizer’s Sutent (sunitinib) and Novartis’Afinitor (everolimus), in the major markets. The expected launch of promising drugs in the forecast period will drive the market.

Anticipated drug launches

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK